Mary Bird Perkins Cancer Center announced that Andy Dalovisio, MD, hematology oncologist, has joined Mary Bird Perkins Cancer Center as the director of its myeloma, lymphoma, and cellular therapy program.
Dalovisio is a board-certified hematologic oncologist with a focus on multiple myeloma, plasma cell disorders, and lymphoma. He obtained a bachelor’s degree at Washington & Lee University in Lexington, Virg., and a medical degree from the Louisiana State University Health Sciences Center in Shreveport. He completed a residency in internal medicine, as well as a fellowship in hematology – oncology, at Rush University Medical Center in Chicago, Ill.
He is a member of several professional organizations including the American Society of Clinical Oncology, American Society of Hematology, International Myeloma Society, and the American Society of Transplant and Cellular Therapy.
“We’re proud to welcome Dr. Dalovisio to the Mary Bird Perkins team,” said Daniel LaVie, MD, Mary Bird Perkins Cancer Center’s director of hematology and oncology. “He comes to us with a wealth of experience, and we look forward to his expertise helping provide the most advanced cancer care to our patients.”
Dalovisio will work at Mary Bird Perkins’ Essen location.